Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma

Phase 2 Terminated 8 enrolled University of Michigan Rogel Cancer Center

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The objective of the trial is to determine the clinical efficacy of ESK981 in combination with nivolumab therapy in patients with metastatic renal cell carcinoma (RCC).

Timeline

Start: 2019-04-11
Primary completion: 2022-10-18
Completion: 2022-10-18

Outcome

Outcome not reported

Stopped: “Lack of patient population”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ESK981	Unknown	160 mg	Oral
Subject	Nivolumab	Monoclonal antibody	480 mg	Intravenous

Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma

Summary

Timeline

Outcome

Drugs

Indications